Skip to content

8:50 am Chair’s Opening Remarks

  • Alan Watt Chief Scientific Officer, Nodthera

Reviewing the Basic Biology & Mechanisms of Action for the Inflammasome

9:00 am Targeting the NLRP3 Inflammasome for the Treatment of Inflammatory Diseases

  • Rebecca Coll Principal Investigator,
    Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast

Synopsis

• NLRP3 signalling pathways
• NLRP3-associated inflammatory diseases
• Rationale for the development of specific NLRP3 inhibitors
• Mechanism of action of the small-molecule NLRP3 inhibitor MCC950

9:30 am The Discovery & Characterisation of a Novel Chemotype for Enhanced NLRP3 Inflammasome Inhibition & Tissue Penetration

Synopsis

• Ester prodrugs provide unprecedented potency against NLRP3-mediated IL-1β production in cellular assays
• Pharmacodynamic impact demonstrated in a proprietary humanised carboxylesterase transgenic mouse
• In a brain perfusion model, ester-containing compounds are highly tissue penetrant

10:00 am Inflammasomes in Infection & Inflammation

Synopsis

• Explore basic mechanisms of inflammasome activation
• Define new role for AIM2 in melanoma
• Mechanisms turning off inflammasome responses

10:30 am Speed Networking

Synopsis

This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the Inflammasome field and establish meaningful business relationships to pursue for the rest of the conference.

11:30 am Morning Refreshments & Networking

Reviewing the Basic Biology & Mechanisms of Action for the Inflammasome

12:00 pm Novel Upstream Target Inhibiting the Inflammasome in Ophthalmic Disease

  • Colin Green Co-founder & Chief Scientific Officer, OcuNexus Therapeutics

Synopsis

  • Explaining the mechanism for inhibiting the nidus for inflammasome assembly by targeting the overexpression of the connexin43 hemichannel and the egress of ATP into the extracellular space
  • Inhibiting the overexpression of Cx43 prevents the continuous recycling and activation of multiple proinflammatory cytokines creating perpetuated inflammation
  • Also presented will be the effect of an orally administered small molecule (Xiflam), a Cx43 inhibitor, on phenotypical models of the “Dry Form” of Macular Degeneration and Diabetic Retinopathy. Phase 2 clinical studies with Xiflam are planned for Q2 2020

12:30 pm Structure of The NLRP3-NEK7 Complex & the Mechanism of NLRP3 Activation

  • Hao Wu Professor, Harvard Medical School

Synopsis

• Structure of the NLRP3-NEK7 complex (published)
• Ongoing elucidation on the mechanism of NLRP3 activation
• Mechanism of small molecule inhibition

1:00 pm Lunch & Networking

Assessing Preclinical Animal Models for Improved Translation into Clinical Trials

2:00 pm How Much Time & Effort Should any Company be Spending on Preclinical Models

  • Steve Glover Co-founder & Chief Executive Officer, ZyVersa Therapeutics

Synopsis

• Transitioning from translational science to commercialization
• Choosing the right animal models for both scientific and commercialization purposes
• Projecting future potential indications while aligning with your near term preclinical requirements

2:30 pm The Discovery & Development of NT-0167, a Potent, Selective NLRP3 Inflammasome Inhibitor

  • Alan Watt Chief Scientific Officer, Nodthera

Synopsis

• NT-0167 demonstrates excellent in vitro and in vivo potency in assays driven NLRP3-mediated IL-1β production
• Characterization in an animal model of Muckle Wells Syndrome (hNLRP3 D305N synthenic mouse) shows excellent efficacy
• Compound is safe to large margins in toxicological studies

3:00 pm Afternoon Refreshments & Networking

Assessing Preclinical Animal Models for Improved Translation into Clinical Trials

4:00 pm Molecular Signals that Activate NLRP3 Inflammasome & Trigger Sterile Inflammation

  • Davide Povero Senior Research Scientist, Department of Biochemistry & Molecular Biology, Mayo Clinic , Previous Jecure Therapeutics Employee

Synopsis

• Role of NLRP3 activation during sterile inflammation
• Danger-associated molecular patterns (DAMPs) that trigger the activation of NLRP3 inflammasome
• Experimental in vitro and in vivo models of NLRP3 inflammasome activation via different stimuli

4:30 pm NLRP3-Dependent IL-1β inhibits CD103+ Dendritic Cell Differentiation in the Gut

Synopsis

• Inflammatory bowel disease (IBD) is associated with enhanced levels of the IL-1 family cytokines IL-1β and IL-18, which are activated by the Nlrp3 inflammasome
• Here, we investigated the role of inflammasome-driven cytokine release on T cell polarization and DC differentiation in steady state and T cell transfer colitis

5:00 pm Chairs Closing Remarks

5:10 pm Scientific Poster Session

Synopsis

After the formal presentations have finished, the learning and networking carries on. The Poster Session allows you to connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships. During this session scientific posters will be presented on the latest advancements in the inflammasome field.